SQZ Biotech
134 Coolidge Ave
Second Floor
Watertown
MA
02472
United States
Tel: (603) 490-9117
Website: http://sqzbiotech.com/
84 articles about SQZ Biotech
-
TScan Therapeutics, Lyell, SQZ Biotech and others secured clearance from the U.S. Food and Drug Administration for their Investigational New Drug Application.
-
He envisions becoming a grandparent in the industry, as opposed to the parenting role he played at Alnylam.
-
SQZ Biotechnologies Announces Healthcare Industry Leader John Maraganore, Ph.D. Joining as Strategic Advisor
1/6/2022
SQZ Biotechnologies today announced that John Maraganore, Ph.D., founding CEO of Alnylam Pharmaceuticals, has joined the company as a strategic advisor.
-
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose
12/2/2021
SQZ Biotechnologies Lead Cell Therapy Candidate Generated Monotherapy Clinical Response Correlated with Substantial CD8 T Cell Tumor Infiltration in HPV+ Solid Tumor at Highest Dose.
-
SQZ Biotechnologies Announces Acceptance by Roche Accelerator in China
12/1/2021
SQZ Biotechnologies Company today announced that its China Initiative has been accepted by the Roche Accelerator.
-
SQZ Biotechnologies to Present at the 4th Annual Evercore ISI HealthCONx Conference
11/29/2021
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the 4th Annual Evercore ISI HealthCONx Conference.
-
SQZ Biotechnologies Presents New AAC, eAPC Platform Research and First Enhanced Tumor Infiltrating Lymphocyte Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting
11/12/2021
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented new SQZ™ AAC and eAPC preclinical research describing the robust potential of these platforms to treat cancer, including data demonstrating synergistic activity when combined with chemotherapy.
-
SQZ Biotechnologies Reports Third Quarter 2021 Financial Results and Recent Portfolio Updates
11/10/2021
SQZ Biotechnologies today reported third quarter 2021 financial results and recent portfolio updates.
-
SQZ Biotechnologies Announces Independent DSMB Recommendation to Advance Lead Cell Therapy Candidate Into Combination With Checkpoint Inhibitors
10/26/2021
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that the independent Data and Safety Monitoring Board for the Phase 1/2 clinical trial SQZ-PBMC-HPV-101 has recommended that the trial advance into the combination stage with checkpoint inhibitors.
-
SQZ Biotechnologies to Present New Data at the Society for Immunotherapy of Cancer Annual Meeting
10/4/2021
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that it will present updates across three oncology programs at various stages of development.
-
SQZ Biotechnologies to Present at the Chardan 5th Annual Genetic Medicines Conference
9/30/2021
SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that management will be presenting at the Chardan 5th Annual Genetic Medicines Conference on October 4.
-
SQZ Biotechnologies to Present at Cantor Global Healthcare Conference
9/27/2021
SQZ Biotechnologies today announced that management will be presenting at the Cantor Global Healthcare Conference on September 29.
-
SQZ Biotechnologies to Present at Upcoming Health Care Conferences - Sep 09, 2021
9/9/2021
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced that management will be presenting at Citi’s 16th Annual Virtual Biopharma Conference on September 10, and at the H. C. Wainwright 23rd Annual Global Investment Conference on September 13.
-
SQZ Biotechnologies Reports Second Quarter 2021 Financial Results and Recent Portfolio Updates
8/4/2021
SQZ Biotechnologies, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, reported second quarter 2021 financial results and recent portfolio updates.
-
SQZ Biotechnologies Presents Regenerative Medicine Data Demonstrating Neuron Generation from Human Pluripotent Stem Cells with Single Delivery of mRNA Transcription Factor
6/23/2021
SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented preclinical regenerative medicine data showing that the company’s Cell Squeeze® technology can be used to generate neurons from induced human pluripotent stem cells through the single delivery of an mRNA encoding fate-specifying transcription factor.
-
SQZ Biotechnologies Tolerizing Antigen Carrier (TAC) Program Induces Antigen-Specific Immune Tolerance in Preclinical Models Demonstrating Potential for Broad Applicability Across Autoimmune Diseases
6/9/2021
Engineered TACs Prevented Hyperglycemia in Type 1 Diabetes Models by Deletion of Target T Cells and Increase of Regulatory T Cells that Exerted Potent Bystander Suppression
-
SQZ Biotechnologies Initial First-In-Human Data Demonstrates Investigational Cell Therapy is Safe and Can Stimulate Immune Responses in Certain Patients with Advanced or Metastatic HPV16+ Tumors
6/4/2021
SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today presented initial results from its ongoing Phase 1 clinical trial
-
SQZ Biotech to Present at Jefferies Virtual Health Care Conference - May 27, 2021
5/27/2021
SQZ Biotechnologies Company, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that management will be participating in the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021.
-
SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors
5/19/2021
SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, will present safety and tolerability, manufacturing, and antitumor activity data from its ongoing Phase 1 clinical trial of SQZ-PBMC-HPV-101 in patients with advanced or metastatic Human Papillomavirus Positive tumors at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
-
SQZ Biotechnologies Reports First Quarter 2021 Financial Results and Recent Business Highlights
5/11/2021
SQZ Biotechnologies Company, a cell therapy company developing novel treatments for multiple therapeutic areas, reported financial results for the period ended March 31, 2021 and reviewed recent business highlights.